Biologics CDMO Europe 2025
Bioconjugation Insights 2025; 1(3), 87–88
DOI: 10.18609/bci.2025.019
As part of our ongoing coverage of key gatherings in life sciences, BioInsights presents a preview of Biologics CDMO Europe 2025. Scheduled for November 19–20, 2025, in Munich, Germany, this summit will unite up to 300 senior manufacturing and external supply-chain experts from across Europe. Focusing on agile, tech-enabled biologics manufacturing, regulatory alignment, and strategic CDMO partnerships, the agenda features off-the-record case studies, executive roundtables, and deep-dive sessions.
Outsourcing strategy and CDMO partner evaluation
A strategic panel including Suyamburam Sathasivam (Associate Vice President, SUN PHARMA), Ulrich Rümenapp (Head of Launch Preparation and Coordination, Bayer), and Daniel Hurni (Former Director of Manufacturing Network Strategy and Business Intelligence, Bristol Myers Squibb) will discuss outsourcing trends toward 2030. Additionally, Christopher Pawlak (External manufacturing Lead, Bayer) will outline practical tools for CDMO partner evaluation, while Andreas Schaaf (Managing Director/CSO, Eleva) will highlight innovations in biomanufacturing technologies. Key sessions will also explore risk allocation in CDMO agreements and resilient partnership models, setting a collaborative tone for navigating Europe’s evolving biologics landscape.
Tech transfer and global regulatory harmonization
The summit will also focus on tech transfer and regulatory compliance for advanced therapies. Christian Simon (Head of Technical Transfer External Manufacturing, Sanofi) will explore how AI-driven predictive maintenance can reduce downtime and improve equipment performance. Jenny Prange (CTO, Muvon Therapeutics) will present strategies for navigating tech transfer in regenerative therapies. Furthermore, a panel on global regulatory harmonization will follow, featuring Pavan Beleyur Narayanaswamy (Head of CMC and Regulatory Affairs, AATec Medical) and Eoin McGrath (Executive Director, ICCBBA).
Cost optimization and evolving contract models
Ulrich Rümenapp (Head of Launch Preparation and Coordination, Bayer) will address strategic approaches to outsourcing CMC development and manufacturing, including IP protection and building effective CDMO partnerships. Giulio Cavalli (Principal Lead, External Manufacturing, Johnson & Johnson Innovative Medicine) will share best practices for managing cross-border tech transfers in a globalized production landscape. The summit will also include a panel discussion on the evolution of contract models in biomanufacturing, featuring Ralf Huss (Managing Director, Biom Biotech Cluster) and Chris Baldwin (Vice President, Manufacturing and Supply, Resolution Therapeutics), who will explore shifting trends and collaborative opportunities in outsourcing agreements.
Biologics CDMO Europe 2025 will convene key stakeholders from across the biologics manufacturing landscape to address the most pressing challenges and innovations shaping the industry, from evaluating CDMO capabilities and optimizing outsourcing strategies to simplifying tech transfer and scaling single-use technologies.
As a reader of the BioInsights journals, you’re entitled to a 15% discount on delegate tickets—just use the code CDMO-Insights! You can find out more about the Biologics CDMO Europe 2025 events here.
To learn about other events coming up in your field, you can find our online Events Calendars here:
Bioconjugation Insights, Cell & Gene Therapy Insights, Nucleic Acid Insights, and Vaccine Insights